VAXIMM AG is a private, clinical stage, Swiss/German biotech developing oral T-cell immunotherapies against cancer. VAXIMM’s technology is based on first-in-class oral T-cell activators that can be readily adapted to target a wide range of cancer-related antigens. Lead product candidate VXM01 is designed to activate T-cells to attack the tumor vasculature, and, in several tumor types, attack cancer cells directly. VXM01 has orphan designation for the EU and the US for glioma.
VAXIMM’s neoantigen program is in preclinical development and has shown immune proof of concept; the Company’s platform allows for fast generation and delivery of personalized T-cell vaccines and may overcome key issues with other neoantigen approaches. A clinical Phase I basket study in collaboration with NEC is currently in preparation. Additional programs are in preclinical development.
VAXIMM AG at a glance:
|Field of Activity||
|Ownership Structure and Financing||
|Technology||VAXIMM‘s plug and play technology is based on first-in-class oral T-cell activators that can be readily adapted to target a wide range of cancer-related antigens. The platform is based on the live attenuated bacterial vaccine strain Ty21, which has been administered to millions of people as a prophylactic vaccine to temporarily protect them from typhoid fever. This strain has been proven to be safe and well tolerated. All immunotherapies resulting from this platform are taken orally by the patient. The platform is suitable for addressing multiple targets with one treatment and can be combined with additional immunotherapies.|
|Date of Incorporation / Number of Employees||2008 / 10|
|Social media||LinkedIn Twitter|